See more : L3Harris Technologies, Inc. (LHX) Income Statement Analysis – Financial Results
Complete financial analysis of Terumo Corporation (4543.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Terumo Corporation, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- Great Elm Capital Corp. 8.50% NOTES DUE 2029 (GECCI) Income Statement Analysis – Financial Results
- Centuria Industrial REIT (CIP.AX) Income Statement Analysis – Financial Results
- CM Life Sciences, Inc. (CMLFU) Income Statement Analysis – Financial Results
- Black Spade Acquisition Co (BSAQ) Income Statement Analysis – Financial Results
- SBI Holdings, Inc. (SBHGF) Income Statement Analysis – Financial Results
Terumo Corporation (4543.T)
About Terumo Corporation
Terumo Corporation engages in the manufacture and sale of medical products and equipment worldwide. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts. The Medical Care Solutions Company segment provides syringes, infusion pumps, syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management and nutritious food products, adhesion barriers, and others; blood glucose monitoring systems, disposable needles for pen-injector, insulin patch pumps, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, cell expansion systems, and others. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was incorporated in 1921 and is headquartered in Tokyo, Japan.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 921.86B | 820.21B | 703.30B | 613.84B | 628.90B | 599.48B | 587.78B | 514.16B | 525.03B | 489.51B | 467.36B | 402.29B | 386.69B | 328.21B | 316.01B | 302.75B | 306.38B | 276.44B | 247.05B | 230.00B | 215.20B | 200.63B | 187,082.10B | 176.05B |
Cost of Revenue | 440.83B | 402.84B | 333.96B | 287.22B | 284.96B | 272.98B | 268.44B | 236.16B | 240.13B | 233.48B | 225.35B | 196.61B | 182.05B | 157.42B | 149.66B | 144.51B | 138.18B | 123.11B | 111.38B | 106.24B | 104.90B | 101.98B | 96.82B | 89.02B |
Gross Profit | 481.04B | 417.37B | 369.34B | 326.62B | 343.93B | 326.50B | 319.33B | 278.00B | 284.90B | 256.03B | 242.01B | 205.69B | 204.64B | 170.80B | 166.35B | 158.24B | 168.20B | 153.33B | 135.67B | 123.77B | 110.29B | 98.65B | 186,985.28B | 87.03B |
Gross Profit Ratio | 52.18% | 50.89% | 52.52% | 53.21% | 54.69% | 54.46% | 54.33% | 54.07% | 54.26% | 52.30% | 51.78% | 51.13% | 52.92% | 52.04% | 52.64% | 52.27% | 54.90% | 55.47% | 54.92% | 53.81% | 51.25% | 49.17% | 99.95% | 49.43% |
Research & Development | 0.00 | 61.60B | 51.80B | 49.10B | 50.60B | 47.70B | 41.34B | 32.38B | 33.15B | 29.36B | 30.13B | 27.13B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 344.98B | 299.86B | 250.89B | 228.57B | 235.14B | 226.33B | 212.36B | 0.00 | 0.00 | 0.00 | 33.00M | 84.41B | 0.00 | 0.00 | 0.00 | 0.00 | 101.26B | 94.87B | 87.42B | 76.66B | 73.64B | 67.35B | 62.23B | 58.23B |
Selling & Marketing | 0.00 | 37.12B | 31.70B | 27.19B | 33.52B | 31.81B | 30.42B | 0.00 | 0.00 | 0.00 | 24.79B | 22.67B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 344.98B | 299.86B | 250.89B | 228.57B | 235.14B | 226.33B | 212.36B | 138.33B | 170.05B | 159.21B | 123.88B | 107.09B | 0.00 | 0.00 | 0.00 | 0.00 | 101.26B | 94.87B | 87.42B | 76.66B | 73.64B | 67.35B | 62.23B | 58.23B |
Other Expenses | -5.90B | 0.00 | 2.49B | -329.00M | -1.82B | -6.47B | -1.58B | -2.01B | -920.00M | -2.67B | -4.47B | -2.28B | -2.52B | -1.57B | 113.00M | -120.00M | 1.00M | 1.00M | 1.00M | 1.00M | 1.00M | 1.00M | 186,895.02B | 1.00M |
Operating Expenses | 339.08B | 300.04B | 253.38B | 228.24B | 233.32B | 219.86B | 210.78B | 201.42B | 203.20B | 188.57B | 176.72B | 152.47B | 141.59B | 108.19B | 103.07B | 104.20B | 101.26B | 94.87B | 87.42B | 76.66B | 73.64B | 67.35B | 186,957.25B | 58.23B |
Cost & Expenses | 781.77B | 702.88B | 587.34B | 515.46B | 518.29B | 492.84B | 479.22B | 437.59B | 443.32B | 422.05B | 402.07B | 349.08B | 323.64B | 265.61B | 252.73B | 248.71B | 239.44B | 217.98B | 198.80B | 182.90B | 178.54B | 169.33B | 187,054.06B | 147.25B |
Interest Income | 3.53B | 2.65B | 1.06B | 1.73B | 1.67B | 2.11B | 1.09B | 497.00M | 665.00M | 566.00M | 459.00M | 307.00M | 309.00M | 269.00M | 388.00M | 1.19B | 2.67B | 2.51B | 2.37B | 1.72B | 1.11B | 1.14B | 2.99B | 1.71B |
Interest Expense | 2.78B | 4.02B | 2.96B | 2.34B | 5.37B | 5.88B | 2.79B | 1.21B | 1.40B | 1.25B | 1.54B | 1.30B | 738.00M | 54.00M | 169.00M | 232.00M | 5.42B | 2.94B | 1.68B | 1.70B | 2.45B | 2.38B | 1.00B | 1.98B |
Depreciation & Amortization | 76.75B | 70.24B | 58.88B | 53.93B | 52.36B | 44.04B | 42.04B | 34.47B | 44.67B | 40.69B | 39.88B | 32.55B | 28.84B | 20.39B | 19.91B | 20.38B | 17.81B | 15.51B | 15.18B | 17.76B | 14.88B | 18.22B | 14.29B | 14.07B |
EBITDA | 219.66B | 188.44B | 175.55B | 151.38B | 162.21B | 147.44B | 150.08B | 111.48B | 126.38B | 108.15B | 105.14B | 86.14B | 79.22B | 72.01B | 83.48B | 72.97B | 83.48B | 72.75B | 67.05B | 63.11B | 51.08B | 41.32B | 40.09B | 42.34B |
EBITDA Ratio | 23.83% | 23.21% | 25.07% | 24.98% | 26.11% | 25.46% | 25.77% | 22.56% | 22.71% | 23.07% | 22.44% | 21.26% | 22.95% | 23.57% | 26.48% | 24.18% | 28.29% | 26.94% | 24.56% | 25.46% | 22.70% | 20.60% | 0.02% | 24.05% |
Operating Income | 140.10B | 117.33B | 115.96B | 98.39B | 110.61B | 106.64B | 108.55B | 76.58B | 81.70B | 67.46B | 65.29B | 53.22B | 63.05B | 62.61B | 63.28B | 54.04B | 66.94B | 58.46B | 48.25B | 47.11B | 36.65B | 31.30B | 28.04B | 28.80B |
Operating Income Ratio | 15.20% | 14.31% | 16.49% | 16.03% | 17.59% | 17.79% | 18.47% | 14.89% | 15.56% | 13.78% | 13.97% | 13.23% | 16.30% | 19.07% | 20.03% | 17.85% | 21.85% | 21.15% | 19.53% | 20.48% | 17.03% | 15.60% | 0.01% | 16.36% |
Total Other Income/Expenses | 733.00M | -1.20B | -1.46B | -1.33B | -4.15B | -3.93B | -1.92B | -12.90B | -4.78B | -3.41B | -12.38B | -931.00M | -13.40B | -11.05B | 124.00M | -1.69B | -1.60B | -1.38B | 3.34B | -3.45B | -2.91B | 2.21B | -3.24B | 213.00M |
Income Before Tax | 140.83B | 116.14B | 114.50B | 97.06B | 106.47B | 102.71B | 106.63B | 74.98B | 76.92B | 64.05B | 52.91B | 52.29B | 49.65B | 51.56B | 63.41B | 52.35B | 65.35B | 57.07B | 51.59B | 43.65B | 33.74B | 33.51B | 24.80B | 29.01B |
Income Before Tax Ratio | 15.28% | 14.16% | 16.28% | 15.81% | 16.93% | 17.13% | 18.14% | 14.58% | 14.65% | 13.08% | 11.32% | 13.00% | 12.84% | 15.71% | 20.06% | 17.29% | 21.33% | 20.65% | 20.88% | 18.98% | 15.68% | 16.70% | 0.01% | 16.48% |
Income Tax Expense | 34.46B | 26.81B | 25.69B | 19.86B | 21.43B | 23.42B | 15.43B | 20.87B | 26.29B | 25.58B | 18.78B | 5.22B | 25.43B | 19.16B | 22.60B | 15.44B | 21.94B | 19.82B | 19.12B | 16.51B | 13.98B | 15.35B | 10.35B | 12.37B |
Net Income | 106.37B | 89.33B | 88.81B | 77.27B | 85.21B | 79.47B | 91.30B | 54.23B | 50.68B | 38.47B | 34.10B | 47.01B | 24.17B | 32.34B | 40.72B | 36.88B | 43.38B | 37.23B | 32.46B | 27.13B | 19.79B | 18.16B | 14.44B | 16.64B |
Net Income Ratio | 11.54% | 10.89% | 12.63% | 12.59% | 13.55% | 13.26% | 15.53% | 10.55% | 9.65% | 7.86% | 7.30% | 11.69% | 6.25% | 9.85% | 12.89% | 12.18% | 14.16% | 13.47% | 13.14% | 11.80% | 9.20% | 9.05% | 0.01% | 9.45% |
EPS | 71.50 | 59.50 | 58.72 | 51.16 | 56.98 | 53.50 | 121.03 | 76.16 | 67.57 | 50.67 | 44.89 | 61.90 | 31.82 | 42.58 | 53.61 | 47.97 | 55.08 | 46.82 | 39.97 | 34.20 | 24.79 | 22.60 | 17.54 | 20.21 |
EPS Diluted | 71.47 | 59.48 | 58.69 | 51.05 | 56.31 | 53.50 | 120.72 | 71.38 | 63.18 | 49.56 | 44.89 | 61.90 | 31.82 | 42.58 | 53.61 | 47.97 | 55.08 | 46.82 | 39.97 | 34.20 | 24.79 | 22.60 | 17.54 | 20.21 |
Weighted Avg Shares Out | 1.49B | 1.50B | 1.51B | 1.51B | 1.50B | 1.49B | 1.49B | 1.49B | 1.49B | 1.49B | 1.49B | 1.49B | 1.49B | 1.49B | 1.49B | 1.49B | 1.49B | 1.49B | 1.49B | 1.49B | 1.49B | 1.49B | 1.49B | 1.49B |
Weighted Avg Shares Out (Dil) | 1.49B | 1.50B | 1.51B | 1.51B | 1.51B | 1.49B | 1.49B | 1.49B | 1.49B | 1.49B | 1.49B | 1.49B | 1.49B | 1.49B | 1.49B | 1.49B | 1.49B | 1.49B | 1.49B | 1.49B | 1.49B | 1.49B | 1.49B | 1.49B |
Source: https://incomestatements.info
Category: Stock Reports